Johnson and Johnson released a plain language summary of the design of their Phase 3 AZALEA trial, which will evaluate the efficacy of nipocalimab in preventing hemolytic disease of the fetus and newborn (HDFN).
The summary describes the design of the AZALEA trial using language that is accessible to a wide range of audiences.
“This summary will help members of the public, including individuals and families affected by HDFN, understand the study,” the authors wrote. “It may also be helpful for health care professionals.”
Plain language summaries are critical for ensuring that the individuals who will be directly impacted by these drugs are kept up-to-date on each stage of drug development. Oftentimes, patients feel excluded from the scientific process due to the use of complex terminology in many scientific communications.
Through this publication, Johnson & Johnson hopes to distill the details of the trial into a more approachable format for readers. The text is divided into sections that answer key questions that individuals may have about the trial, many of which have accompanying infographics.
Read more about the AZALEA study
After reading the summary, patients can expect to better understand the risk factors, causes and symptoms of HDFN; the mechanism of action of nipocalimab and key outcomes of previous studies assessing the therapy; and details on the study design of AZALEA, including its location, time frame and methodology.
It is not often that pharmaceutical companies create plain language summaries of their work. However, they serve both to reassure and educate readers, creating an informed patient population that feels more in control of their medical journeys.
AZALEA is the first multi-center, global study to investigate the safety of nipocalimab and its ability to prevent or reduce serious adverse effects of HDFN.
Nipocalimab functions by blocking the neonatal Fc receptor (FcRn), which normally promotes the passage of a type of antibody called immunoglobulin G (IgG) across the placenta. The drug decreases maternal levels of IgG and its transfer to the fetus, thereby helping to prevent HDFN.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
